Find VIC-1911 manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Tas-119, 1453099-83-6, Tas 119 [who-dd], 6a57j83j27, 4-piperidinecarboxylic acid, 1-(2,3-dichlorobenzoyl)-4-((5-fluoro-6-((5-methyl-1h-pyrazol-3-yl)amino)-2-pyridinyl)methyl)-, 1-(2,3-dichlorobenzoyl)-4-((5-fluoro-6-((5-methyl-1h-pyrazol-3-yl)amino)pyridin-2-yl)methyl)piperidine-4-carboxylic acid
Molecular Formula
C23H22Cl2FN5O3
Molecular Weight
506.4  g/mol
InChI Key
PLAVWQHGBMTMFR-UHFFFAOYSA-N
FDA UNII
6A57J83J27

VIC-1911
1 2D Structure

VIC-1911

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-(2,3-dichlorobenzoyl)-4-[[5-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyridin-2-yl]methyl]piperidine-4-carboxylic acid
2.1.2 InChI
InChI=1S/C23H22Cl2FN5O3/c1-13-11-18(30-29-13)28-20-17(26)6-5-14(27-20)12-23(22(33)34)7-9-31(10-8-23)21(32)15-3-2-4-16(24)19(15)25/h2-6,11H,7-10,12H2,1H3,(H,33,34)(H2,27,28,29,30)
2.1.3 InChI Key
PLAVWQHGBMTMFR-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=CC(=NN1)NC2=C(C=CC(=N2)CC3(CCN(CC3)C(=O)C4=C(C(=CC=C4)Cl)Cl)C(=O)O)F
2.2 Other Identifiers
2.2.1 UNII
6A57J83J27
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 1-(2,3-dichlorobenzoyl)-4-((5-fluoro-6-((5-methyl-1h-pyrazol-3-yl)amino)pyridin-2-yl)methyl)piperidine-4-carboxylic Acid

2. Tas-119

2.3.2 Depositor-Supplied Synonyms

1. Tas-119

2. 1453099-83-6

3. Tas 119 [who-dd]

4. 6a57j83j27

5. 4-piperidinecarboxylic Acid, 1-(2,3-dichlorobenzoyl)-4-((5-fluoro-6-((5-methyl-1h-pyrazol-3-yl)amino)-2-pyridinyl)methyl)-

6. 1-(2,3-dichlorobenzoyl)-4-((5-fluoro-6-((5-methyl-1h-pyrazol-3-yl)amino)pyridin-2-yl)methyl)piperidine-4-carboxylic Acid

7. Tas119

8. Chembl3692206

9. Schembl16341234

10. Unii-6a57j83j27

11. Gtpl12070

12. Vic1911

13. Ex-a5696

14. Vic 1911

15. Example 1 [us10092556b2]

16. Hy-137377

17. Cs-0138153

18. A936878

2.4 Create Date
2013-09-16
3 Chemical and Physical Properties
Molecular Weight 506.4 g/mol
Molecular Formula C23H22Cl2FN5O3
XLogP34.4
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count7
Rotatable Bond Count6
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area111
Heavy Atom Count34
Formal Charge0
Complexity741
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)


Protein Kinase Inhibitors

Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)


ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty